Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Inclusion criteria

* Eligible for treatment with cilta-cel per United States Prescribing Information (USPI) * Has serious or life-threatening multiple myeloma per USPI, and where re-apheresis, re-manufacturing, or other anti-myeloma directed therapy is not considered feasible or adequate per treating physician discretion * Favorable participant benefit/risk assessment determined by Janssen medical review * Treating physician confirms the favorable risk benefit profile, and that proceeding with this treatment is in the best interest of the participant * Able to provide informed consent indicating they understand the purpose of this expanded access program (EAP) * A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hCG\]) pregnancy test during screening and prior to the first dose of cyclophosphamide and fludarabine